NCT07294144招募中2 期
A Study to Evaluate the Biological Effect of Tofersen in Adults With Amyotrophic Lateral Sclerosis Without Mutations in SOD1
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Proportion of participants with ≥30% reduction in plasma NfL
研究概览
简要总结
The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS. The main questions it aims to answer are:
- Does tofersen lower the levels of neurofilament light chain (NfL) in the blood and CSF of adult participants with non-SOD1 ALS?
- Is tofersen safe and tolerable for adult participants with non-SOD1 ALS?
- Does tofersen affect other measurements such as clinical outcomes and quality-of-life measures in participants with non-SOD1 ALS?
Participants will :
- Receive 100mg tofersen via lumbar puncture for 24 weeks. The doses are at the following time points: Weeks 0, 2, 4, 8, 12, 16, 20, and 24.
- Complete 2 follow-up visits following the end of the dosing period at Weeks 28 and 32.
- Complete a variety of questionnaires and outcome measurements such as strength and breathing testing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use PHI in accordance with national and local participant privacy regulations.
- •Aged 18 years or older at the time of informed consent.
- •Confirmed diagnosis of ALS.
- •Time since onset of weakness due to ALS ≤ 24 months at the time of the screening visit.
- •Prior confirmed genetic testing negative for SOD1 and FUS mutations. Participants with mutations in genes other than SOD1 and FUS may be enrolled at the discretion of the Site Investigator.
- •SVC ≥ 50% of predicted value as adjusted for sex, age, and height (from the sitting position).
- •Medically able to undergo the study procedures and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.
- •All participants must agree to practice effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.
- •If taking riluzole, participant must be on a stable dose for ≥ 30 days prior to Day 1 and expected to remain at that dose until the final study visit.
- •If taking edaravone, participant must have initiated edaravone ≥ 60 days (2 treatment cycles) prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study.
排除标准
- •Treatment with another investigational drug (including investigational drugs for ALS through compassionate use or expanded access programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.
- •Current enrollment in any other interventional study.
- •History of drug abuse or alcoholism within ≤ 6 months of study enrollment that would limit participation in the study, as determined by the Investigator.
- •Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period.
- •Ongoing medical condition (e.g., wasting or cachexia, severe anemia) that according to the Investigator would interfere with the conduct or assessments of the study.
- •History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in neurofilament, in the opinion of the Investigator.
- •Female participants who are pregnant or currently breastfeeding.
- •Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression ≤ 90 days, as determined by the Investigator.
- •History of allergies to a broad range of anesthetics.
- •Tracheostomy.
- •Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding. These could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand's disease, liver disease).
- •Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication that cannot be safely held before and/or after an LP procedure according to local or institutional guidelines and/or Investigator determination.
- •Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter.
- •Clinically significant abnormalities in hematology or clinical chemistry parameters, as determined by the Investigator, which would render the participant unsuitable for enrollment.
- •Inability to comply with study requirements.
- •Other unspecified reasons that, in the opinion of the Investigator, make the participant unsuitable for enrollment.
研究组 & 干预措施
Tofersen
Experimental
干预措施: Tofersen (Drug)
结局指标
主要结局
Proportion of participants with ≥30% reduction in plasma NfL
时间窗: From Baseline to Week 28
次要结局
- Proportion of participants with ≥ 30% reduction in CSF NfL(From Baseline to Week 28)
- Change in plasma and CSF NfL levels(From Baseline to Week 28)
- Incidence of adverse events and serious adverse events(From Baseline through study completion, an average of 8 months)
研究者
Timothy M. Miller, MD, PhD
David Clayson Professor of Neurology
Washington University School of Medicine
研究点 (3)
Loading locations...
相似试验
招募中
不适用
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)NCT07259980Biogen125
进行中（未招募）
3 期
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 MutationAmyotrophic Lateral Sclerosis Associated With a SOD1 Gene MutationNCT04856982Biogen158
进行中（未招募）
不适用
Expanded Clinical Study of Tofersen (BIIB067) in SOD1-ALSjRCT2071240022Biogen Japan Ltd.20
进行中（未招募）
2 期
托吡司特片治疗痛风伴高尿酸血症的有效性和安全性的多中心、随机、双盲双模拟、平行、阳性药对照的 II 期临床研究CTR20251358120
撤回
3 期
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate CancerRisk of Bone Fracture OccurrencesNCT01214291GTx